{"id":"W2148766438","doi":"10.1016/s0140-6736(12)61769-3","title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1198,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital; McGill University","funders":"National Institute for Health and Care Research","keywords":"Alemtuzumab; Medicine; Interferon beta-1a; Multiple sclerosis; Internal medicine; CD52; Clinical endpoint; Randomized controlled trial; Gastroenterology; Interferon beta; Immunology; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002626549,0.002596505,0.005337767,0.000621927,0.0007543467,0.001601837,0.001324106,0.003268196,0.006386974],"category_scores_gemma":[0.003368804,0.000884236,0.004412381,0.0006942677,0.001671192,0.001626522,0.0006850332,0.004381596,0.001158469],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0013442,"about_ca_system_score_gemma":0.001582264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001825003,"about_ca_topic_score_gemma":0.002355742,"domain_scores_codex":[0.9988486,0.0006589728,0.00007357492,0.0001642971,0.00007011522,0.0001844406],"domain_scores_gemma":[0.9983546,0.000596054,0.0003738582,0.0001537129,0.00008421431,0.0004375433],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9908932,0.001261727,0.000226111,0.0003772607,0.0009122691,0.00003144476,0.0000342878,0.0001638676,0.0006626309,0.00004603302,0.0003167213,0.00507435],"study_design_scores_gemma":[0.9870076,0.01172303,0.000444344,0.00002564795,0.0003636761,0.00001549805,0.000009241324,0.0001025779,0.00006638725,0.00007668311,0.0001582475,0.000007105978],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9759495,0.01271472,0.0008642644,0.001914987,0.001526656,0.003637034,0.001164302,0.0001644313,0.002064179],"genre_scores_gemma":[0.9804987,0.004950339,0.00182027,0.002119747,0.0008718793,0.005287116,0.001090996,0.00004158765,0.003319394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006386974,"threshold_uncertainty_score":0.02136654,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1458615041298442,"score_gpt":0.3623954771154779,"score_spread":0.2165339729856337,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}